BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, March 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 27, 2010
View Archived Issues
What T-DM1 Means for Roche And Biotechs on the AA Path
Read More
Firms Opt for Regional Deals on Road to Larger Markets
Read More
Money Raised Year to Date
Read More
Money Raised By Biotech in 2010
Read More
Week in Review
Read More
Week in Washington
Read More
Word on the Street
Read More
U.S. Public Offering Performance By Underwriter: Jan. 1 - Aug. 31, 2010
Read More
Underwriters' Performance on IPOs: Jan. 1 - Aug. 31, 2010
Read More
Underwriters' Performance on IPOs: Jan. 1 – Aug. 31, 2010
Read More
Lead Underwriter Performance on All U.S. Offerings: Jan. 1 – Aug. 31, 2010
Read More
Stock Gainers and Losers For The Week
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More
Debate Sparked Over Recent Rulings, but What's Changed?
After 17 years of smooth sailing – Iressa (gefitinib, AstraZeneca plc) notwithstanding – the FDA's accelerated approval process seems to have hit some choppy waters.
Read More